Browse 157 market data Tables and 52 Figures spread through 213 Pages and in-depth TOC on "Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Hematology, Rheumatology, Immunology) End User (Hospitals, Clinical Research Laboratories) - Global Forecast to 2021"
https://www.marketsandmarkets.com/Market-Reports/plasma-fractionation-market-93798284.html

The global plasma fractionation market is estimated to grow at a CAGR of 6.7% from 2016 to 2021 to reach USD 26.07 Billion by 2021. Growing aging population, rising incidences of bleeding and immune disorders, and growing use of immunoglobulin and alpha-1-antitrypsin are expected to propel the growth of this market. However, the high cost of plasma products, adverse reactions associated with use of products, and limited reimbursement policies can hinder the growth of this market. Moreover, the increasing usage of recombinant coagulation factors as an alternative to plasma-derived coagulation factors is further hampering the growth of this market to a certain extent.

In this report, the global plasma fractionation market is segmented on the basis of products, applications, end users, and regions. On the basis of products, the market is further segmented into albumin, immunoglobulin, coagulation factor concentrates, protease inhibitors, and other plasma products. The immunoglobulin segment accounted for the largest share of the market in 2015, owing to increased number of neurological and immunology diseases, increasing off-label indications of intravenous immunoglobulin (IVIg), and growing use of subcutaneous immunoglobulin (SCIg) due to its ease of administration and reduced administration time.

Based on application types, the plasma fractionation market is segmented into neurology, immunology, hematology, pulmonology, hemato-oncology, rheumatology, critical care, and other applications. Similarly, on the basis of end-users, the market is segmented into hospitals and clinics, clinical research laboratories, and academic institutes.

Geographically, the global plasma fractionation market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. In 2015, North America commanded a major share of the market. However, Asia-Pacific is expected to witness the highest growth rate during the forecast period. Growth in the Asia-Pacific market can be attributed to the increasing aging population, growing use of albumin and immunoglobulin, and increasing focus on better diagnosis, prophylactic treatments, and medical research.

Some of the prominent players in the global plasma fractionation market include CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), China Biologic Products, Inc. (China), Biotest AG (Germany), LFB S.A (France), Bio Product Laboratory Ltd. (U.K.), and Sanquin (Netherlands).